Missing values [Study Per­for­mance]

posted by Helmut Homepage – Vienna, Austria, 2008-07-30 19:14 (6542 d 00:13 ago) – Posting: # 2109
Views: 20,862

Dear Martin,

I’m with you in the definition of data sets (especially PKAS(b) etc. etc.)…
The important point is an a-priori strategy, which has to be adapted according to the PK characteristics of the drug, etc.

❝ regarding the importance of FADS and PADS: the FADS should reflect the clinical situation in practice better than the rather artificial PADS and is according to my point of view more important.


Yes, but phase I trials never reflect the clinical situation.
IMPs in a BE study are not labeled for sole use in healthy male Caucasian* subjects, preferably non-smokers of a BMI [19-27] fasting four hours after administration together with 150 mL non-carbonated water of ambient temperature avoiding methyl-xanthine containing food and beverages as well as grapefruit juice, charcoal broiled meat and broccoli during the study (did I forget something?). :cool:
A properly designed BE study should be powered to be able to detect differences between formulations in the smallest possible number of subjects – which we hope to attain by a high degree of standardization. This has nothing in common with the clinical situation.

❝ […] thanks for the very interesting discussion


Same to you!



Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
387 visitors (0 registered, 387 guests [including 23 identified bots]).
Forum time: 19:28 CEST (Europe/Vienna)

The real struggle is not between the right and the left
but between the party of the thoughtful
and the party of the jerks.    Jimmy Wales

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5